🧬 Circulating tumor cells (CTCs) re-emerge as a complement to ctDNA in liquid biopsies: tumor heterogeneity, protein biomarkers, drug resistance & minimal residual disease. 📖 @Cancer_Cell .👉 #CánCare #oncology #liquidbiopsy

🫁 EGFR mutations reshaped NSCLC care. TKIs now impact early, locally advanced, and metastatic disease. Biomarkers and resistance insights guide precision strategies for better outcomes. 📖 @CACancerJournal .DOI 👉 10.3322/caac.70024. #CánCare #NSCLC #EGFR #lcsm

Join millions who have switched to Grok.

📌 Prostate cancer remains the most common non-skin cancer in men, with >1.4M cases annually worldwide. Advances in risk stratification, AR pathway inhibitors & chemo are reshaping management, but metastatic disease survival is still poor. 📖 @JAMA_current .DOI 👉🏻

🚨 Cancer of unknown primary (CUP) has long been a therapeutic challenge with poor outcomes. New data show that molecularly guided therapy and immunotherapy can improve survival, while ctDNA, methylation profiling, and AI-based pathology enable precision strategies. 📖

🧠 Updated RANO/EANO guideline: Amino acid PET outperforms glucose PET in glioma management. Still, class 1 evidence for outcome benefit is scarce, key priority for future trials. 📖 @TheLancetOncol .DOI 👉🏻 . #CánCare #oncology #glioma #neurooncology

RT @NEJM: Original Article: Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer (CheckMate 816 phase 3 trial) http….

RT @jsoriamd: Circulating Tumor Cells: Beyond ctDNA in Precision Oncology.🩸CTCs ≠ ctDNA: Beyond mutations, CTCs reveal real-time protein &….

RT @StephenVLiu: How common is rebiopsy after progression on targeted therapy for NSCLC? Report @ClinicalLung included 148 pts with EGFR, A….

📌 Defining resectable stage III NSCLC remains challenging. Systematic review (EORTC) shows key factors:.❌ N3, bulky N2, invasive tumors.✅ Single-station N2, cT3N1. 👉 Multidisciplinary decision-making essential. 📖 @LungCaJournal .🔗 #CánCare #NSCLC

⏱️ The long-term effects of chemotherapy on normal blood cells. Chemotherapy not only damages tumor cells but can also leave long-lasting mutations in normal blood cells, resembling accelerated aging. 📖 @NatureGenet .DOI 👉🏻 #CánCare #oncology #chemo

🧬 In aRCC, MSKCC and IMDC models retain prognostic value for ~2y with sunitinib but attenuate with long-term survivors and with nivolumab+ipilimumab. 5y OS: 48% vs 37%. New models are needed in the ICI era. 📖 @JCOOP_ASCO .DOI 👉🏻 #CánCare #oncology

🧬 LIQUIK study. In metastatic #NSCLC, LiquidHALLMARK (ctDNA+ctRNA) improved biomarker detection vs ctDNA alone:.🔹 +28.6% gene rearrangements.🔹 +15.6% actionable biomarkers. Tissue NGS remains gold standard, but ctRNA enhances liquid biopsy yield. @JCOPO_ASCO .👉

🧬 Next-gen cancer nanomedicine uses engineered nanoparticles with smart surface modifications to bypass barriers, prolong circulation, and precisely deliver therapy to tumors and immune/stromal cells. @NatureRevCancer .DOI: #CánCare #oncology

🦠 Gut microbiota influences response, resistance, and toxicity to ICIs. Antibiotic use before/during therapy worsens survival, underscoring the need for stewardship. Microbiota-based strategies (FMT, live bacteria, diet) are emerging. 📖 @ASCO #EdBook.DOI 👉🏻

🧠 Brain metastases exploit adaptive metabolism of glucose, fatty acids, and amino acids to survive in the brain microenvironment. Distinct profiles in proliferative vs dormant cells reveal why a one-size-fits-all strategy falls short. 📖 @NatureRevCancer .DOI 👉🏻

🌎 Renal cancer burden is rising: 434,840 new cases and 155,953 deaths in 2022, projected to reach 745,791 cases (+72%) and 304,861 deaths (+96%) by 2050. Genetics and modifiable risks like obesity, HTN, and smoking are key drivers. 📖 @EUplatinum .DOI 👉🏻

🔔 Testicular cancer is the most common solid tumor in people with testicles aged 15–44. A @TheLancet seminar reviews management of seminoma and non-seminoma, follow-up, relapse strategies, and future directions. DOI 👉🏻 #CánCare #oncology

Next-gen immunotherapies are tackling resistance to ICIs in lung cancer, with bispecific antibodies like ivonescimab (PD-1×VEGF) and tarlatamab (DLL3×CD3) paving the way for new standards of care. 📖 @NatRevClinOncol .DOI 👉🏻 #CánCare #NSCLC #SCLC